Enzolytics Inc. (ENZC)
Enzolytics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Plano, TX, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $2.4M. On trailing twelve-month figures it carries a trailing P/E of -9.34, a net margin of 0.0%. Its beta of 0.49 implies it has historically moved less than the broad market.
Enzolytics Inc., a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies. Its primary focus is on addressing severe infectious illnesses. The company possesses patented anti-HIV treatments that have successfully completed clinical testing. Additionally, Enzolytics has developed a unique methodology for manufacturing human IgG1 monoclonal antibodies, intended to provide non-toxic passive immunotherapy against various infectious diseases. A significant achievement includes the creation of a proprietary cell line, specifically engineered to produce human monoclonal antibodies that effectively target and neutralize the human immunodeficiency virus (HIV).
Enzolytics Inc. is most often compared with the following Healthcare names: